293 related articles for article (PubMed ID: 26856942)
1. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
Datt J; Baldock L; Pull E; Webber B
Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
[TBL] [Abstract][Full Text] [Related]
2. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
[TBL] [Abstract][Full Text] [Related]
3. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Meissner A; Limmroth V
Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
[TBL] [Abstract][Full Text] [Related]
4. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
[TBL] [Abstract][Full Text] [Related]
5. The autonomic balance predicts cardiac responses after the first dose of fingolimod.
Rossi S; Rocchi C; Studer V; Motta C; Lauretti B; Germani G; Macchiarulo G; Marfia GA; Centonze D
Mult Scler; 2015 Feb; 21(2):206-16. PubMed ID: 24957049
[TBL] [Abstract][Full Text] [Related]
6. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
DiMarco JP; O'Connor P; Cohen JA; Reder AT; Zhang-Auberson L; Tang D; Collins W; Kappos L
Mult Scler Relat Disord; 2014 Sep; 3(5):629-38. PubMed ID: 26265275
[TBL] [Abstract][Full Text] [Related]
7. A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure.
Ramseier SP; Roth S; Czaplinski A
BMC Pharmacol Toxicol; 2015 Apr; 16():7. PubMed ID: 25889400
[TBL] [Abstract][Full Text] [Related]
8. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.
Bermel RA; Hashmonay R; Meng X; Randhawa S; von Rosenstiel P; Sfikas N; Kantor D
Mult Scler Relat Disord; 2015 May; 4(3):273-80. PubMed ID: 26008945
[TBL] [Abstract][Full Text] [Related]
10. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
[TBL] [Abstract][Full Text] [Related]
11. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
Limmroth V; Ziemssen T; Lang M; Richter S; Wagner B; Haas J; Schmidt S; Gerbershagen K; Lassek C; Klotz L; Hoffmann O; Albert C; Schuh K; Baier-Ebert M; Wendt G; Schieb H; Hoyer S; Dechend R; Haverkamp W
BMC Neurol; 2017 Jan; 17(1):11. PubMed ID: 28100182
[TBL] [Abstract][Full Text] [Related]
12. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
13. Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.
Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
Mult Scler Relat Disord; 2016 Nov; 10():86-89. PubMed ID: 27919506
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
Vanoli E; Montano N; De Angelis G; Badilini F; Mirabella M; Bonavita S; Patti F; Bianco A; Sparaco M; Chisari C; Laroni A; Frigerio F; Bartezaghi M; Rossi S; Turrini R; Mancardi G
J Neurol Sci; 2019 Oct; 405():116423. PubMed ID: 31520869
[TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
[TBL] [Abstract][Full Text] [Related]
16. Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring.
Lapierre Y; O'Connor P; Devonshire V; Freedman MS; Kremenchutzky M; Yeung M; Schecter R
Can J Neurol Sci; 2016 Mar; 43(2):278-83. PubMed ID: 26890887
[TBL] [Abstract][Full Text] [Related]
17. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
Kocyigit D; Yalcin MU; Gurses KM; Tokgozoglu L; Karabudak R
Mult Scler Relat Disord; 2019 Jan; 27():276-280. PubMed ID: 30447536
[TBL] [Abstract][Full Text] [Related]
18. Heart rate variability decreases after 3 months of sustained treatment with fingolimod.
Vehoff J; Haegele-Link S; Humm A; Kaegi G; Mueller SK; Sauter R; Tettenborn BE; Hundsberger T
J Neurol; 2017 Nov; 264(11):2313-2317. PubMed ID: 28993873
[TBL] [Abstract][Full Text] [Related]
19. Early safety and efficacy of fingolimod treatment in Denmark.
Voldsgaard A; Koch-Henriksen N; Magyari M; Sellebjerg F; Sørensen PS; Oturai AB
Acta Neurol Scand; 2017 Jan; 135(1):129-133. PubMed ID: 27910101
[TBL] [Abstract][Full Text] [Related]
20. Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.
Hilz MJ; Intravooth T; Moeller S; Wang R; Lee DH; Koehn J; Linker RA
PLoS One; 2015; 10(7):e0132139. PubMed ID: 26147106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
